Granisetron Articles
Batch of Japanese drug approvals, including for Taiho, Daiichi Sankyo and three for Novartis
20 January 2010
AP Pharma cuts workforce by 34%
29 May 2009
ProStrakan's 2008 revenue up 23%
30 March 2009
Stock Commentary - Europe - week to Feb 16, 2009
23 February 2009
ProStrakan signs two Sancuso marketing deals
16 February 2009
ProStrakan's Sancuso launched in USA
10 November 2008
AP Pharma's APF530 ready for submission
6 October 2008
Study supports palonosetron's delayed phase CINV action
22 September 2008
JapanBridge to market Sancuso in SE Asia
2 June 2008
FDA clears APP's Polmyxin B Sulfate
21 January 2008
ProStrakan's 2007 sales exceed expectations
21 January 2008
Barr's generic Kytril gains final FDA approval
7 January 2008
NovaQuest signs accord on ProStrakan's Sancuso
29 October 2007
ProStrakan's 1st-half revenues jump 28%
24 September 2007
ProStrakan out-licenses Sancuso in S Korea
20 August 2007
ProStrakan submits Sancuso MAA
23 July 2007
ProStrakan narrows 2006 loss to L18.3M
9 April 2007
Stock Commentary - Europe - week to Dec 11, 2006
18 December 2006
Japan's generic drugs market expected to grow 8.8% from 2006 to 2008
27 November 2006
China' SFDA clears China Pharma's granisetron
16 October 2006
ProStrakan half-year sales up 28% to L16.1M
25 September 2006
Japan stock market week to March 27, 2006
3 April 2006
ProStraken provides update on Sancuso and Tostrex trials
13 February 2006
AP Pharma submits APF530 trial protocol to FDA
30 January 2006
A P Pharma starts Ph I trial of APF530
26 April 2004
Roche profits hit by weak foreign currency
19 August 2002
MGI to file nausea drug after FDA meeting
13 May 2002
Tokyo pharma stocks - week to April 8
15 April 2002
French price cuts for GSK, Lilly, Merck drugs
16 August 2001
Net income leaps 50% at Roche in 2000, but pharma sales disappoint
28 February 2001
GSK restructuring its R&D to boost productivity
22 February 2001
Roche plans Tamiflu launch in Japan soon
23 January 2001
GlaxoSmithKline on December 27?
13 December 2000
Glaxo Wellcome/SmithKline Beecham merger still dogged by FTC demands
16 November 2000
SmithKline submits Kytril price documents
13 September 2000
GW/SB merger delayed until end of year
11 September 2000
US House panel seeks SB's Kytril price data
6 September 2000
SB sells Kytril, Famvir and Vectavir for $2.9bn
31 August 2000
GW and SB being made to wait by FTC
16 June 2000
Coulter reacquires ex-USA Bexxar rights
26 April 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
SB's Kytril OKed for new indication
3 August 1999
Merck disappointment as highly-touted antidepressant stalls
26 January 1999
SB To Jointly Commercialize Coulter's Cancer Therapy
8 December 1998
SB Defends Independence On Strong R&D Grounds
23 April 1998
Anzemet Launched For PONV In USA
26 February 1998
Currency Hits SmithKline Beecham Sales And Profits
17 February 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
Strong Sterling Hits 3rd Qtr Profits At SB
22 October 1997
Strong Sterling Impacts SmithKline Beecham
23 July 1997
HMR's Anzemet "Approvable" In USA
17 March 1997
New Products Drive Strong Growth At SB
24 February 1997
SmithKline Beecham 3rd Qtr Earnings Leap 20%
28 October 1996
Dilemma For Imported Drugs In China
5 August 1996
HMR Files NDA for Dolasetron
22 April 1996
SB Trading Profit Up 19% On New Prods
26 February 1996
SmithKline Beecham Meets Expectations In 1995 3rd Qtr
30 October 1995
SmithKline B Seiyaku KK: Kytril
18 September 1995
Interest Expenses, Currency Hit SB's Results
31 July 1995
....And Marion Merrell Dow Updates On R&D Efforts
10 April 1995
European Stock Comment
27 March 1995
Indication Extension For SB's Infanrix
27 March 1995
For SmithKline Beecham 1994 Was "Successful Year"
27 February 1995
Glaxo Interim Profits Up 10% On 2% Sales Rise
13 February 1995
Analysts Upgrade SmithKline Beecham
31 October 1994
Anderson Center Formulary
31 October 1994
SmithKline Beecham On Adapting To Change
10 October 1994
Benefits From PBM/MPC Acquisitions Assessed
15 August 1994
Poor Prospects For Zofran In Face Of Cost Constraints
8 August 1994
SB Lifts 2nd Qtr Earnings 20%
25 July 1994
SB Sets US Price For Famvir At Same Level As Zovirax
18 July 1994
1ST HEAD-TO-HEAD KYTRIL/ZOFRAN STUDY
11 July 1994
NIPPON GLAXO LAUNCHES ZOFRAN IN JAPAN
16 May 1994
SMITHKLINE BEECHAM'S MIXED 1st QTR
2 May 1994
CHEAPER KYTRIL LAUNCHED IN USA
11 April 1994
SERTONE LAUNCH
28 February 1994
GLAXO CONSIDERS OPTIONS FOR USA
28 February 1994
SMITHKLINE BEECHAM PLEASED WITH RESULTS
28 February 1994
GLAXO'S ZOFRAN APPROVED IN JAPAN
24 January 1994
EUROPE STOCK COMMENT
10 January 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
KYTRIL GAINS APPROVABLE STATUS
20 December 1993
ANALYSTS FORECAST FDA YEAR-END APPROVALS
13 December 1993
GLAXO REAFFIRMS COMMITMENT TO R&D
6 December 1993
GLAXO'S DEFENDS ONDANSETRON ROLE
29 November 1993
STUDY SHOWS PATIENTS PREFER GRANISETRON
22 November 1993
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
